Literature DB >> 22056479

Dexamethasone counteracts the immunostimulatory effects of triiodothyronine (T3) on dendritic cells.

María M Montesinos1, Vanina A Alamino, Iván D Mascanfroni, Sebastián Susperreguy, Nicolás Gigena, Ana M Masini-Repiso, Gabriel A Rabinovich, Claudia G Pellizas.   

Abstract

Glucocorticoids (GCs) are widely used as anti-inflammatory and immunosuppressive agents. Several studies have indicated the important role of dendritic cells (DCs), highly specialized antigen-presenting and immunomodulatory cells, in GC-mediated suppression of adaptive immune responses. Recently, we demonstrated that triiodothyronine (T3) has potent immunostimulatory effects on bone marrow-derived mouse DCs through a mechanism involving T3 binding to cytosolic thyroid hormone receptor (TR) β1, rapid and sustained Akt activation and IL-12 production. Here we explored the impact of GCs on T3-mediated DC maturation and function and the intracellular events underlying these effects. Dexamethasone (Dex), a synthetic GC, potently inhibited T3-induced stimulation of DCs by preventing the augmented expression of maturation markers and the enhanced IL-12 secretion through mechanisms involving the GC receptor. These effects were accompanied by increased IL-10 levels following exposure of T3-conditioned DCs to Dex. Accordingly, Dex inhibited the immunostimulatory capacity of T3-matured DCs on naive T-cell proliferation and IFN-γ production while increased IL-10 synthesis by allogeneic T cell cultures. A mechanistic analysis revealed the ability of Dex to dampen T3 responses through modulation of Akt phosphorylation and cytoplasmic-nuclear shuttling of nuclear factor-κB (NF-κB). In addition, Dex decreased TRβ1 expression in both immature and T3-maturated DCs through mechanisms involving the GC receptor. Thus GCs, which are increased during the resolution of inflammatory responses, counteract the immunostimulatory effects of T3 on DCs and their ability to polarize adaptive immune responses toward a T helper (Th)-1-type through mechanisms involving, at least in part, NF-κB- and TRβ1-dependent pathways. Our data provide an alternative mechanism for the anti-inflammatory effects of GCs with critical implications in immunopathology at the cross-roads of the immune-endocrine circuits.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22056479     DOI: 10.1016/j.steroids.2011.10.006

Source DB:  PubMed          Journal:  Steroids        ISSN: 0039-128X            Impact factor:   2.668


  7 in total

1.  Peripheral blood natural killer cells and mild thyroid abnormalities in women with reproductive failure.

Authors:  P Triggianese; C Perricone; P Conigliaro; M S Chimenti; R Perricone; C De Carolis
Journal:  Int J Immunopathol Pharmacol       Date:  2015-12-10       Impact factor: 3.219

2.  Antitumor Responses Stimulated by Dendritic Cells Are Improved by Triiodothyronine Binding to the Thyroid Hormone Receptor β.

Authors:  Vanina A Alamino; Iván D Mascanfroni; María M Montesinos; Nicolás Gigena; Ana C Donadio; Ada G Blidner; Sonia I Milotich; Sheue-Yann Cheng; Ana M Masini-Repiso; Gabriel A Rabinovich; Claudia G Pellizas
Journal:  Cancer Res       Date:  2015-02-11       Impact factor: 12.701

3.  The thyroid hormone triiodothyronine reinvigorates dendritic cells and potentiates anti-tumor immunity.

Authors:  V A Alamino; M M Montesinos; G A Rabinovich; C G Pellizas
Journal:  Oncoimmunology       Date:  2015-07-01       Impact factor: 8.110

4.  Generation of inducible immortalized dendritic cells with proper immune function in vitro and in vivo.

Authors:  Cornelia Richter; Sebastian Thieme; Joanna Bandoła; Magdalena Laugsch; Konstantinos Anastassiadis; Sebastian Brenner
Journal:  PLoS One       Date:  2013-04-23       Impact factor: 3.240

5.  Recombinant Human Thyroid-Stimulating Hormone Increases the Percentages of Natural Killer T Cells and B Lymphocytes in Human Peripheral Blood In Vivo.

Authors:  Zbigniew Adamczewski; Mariusz Stasiołek; Arkadiusz Zygmunt; Przemysław W Śliwka; Katarzyna Wieczorek-Szukała; Andrzej Lewiński
Journal:  Front Endocrinol (Lausanne)       Date:  2020-11-20       Impact factor: 5.555

Review 6.  Drug Repurposing to Enhance Antitumor Response to PD-1/PD-L1 Immune Checkpoint Inhibitors.

Authors:  Xavier Thuru; Romain Magnez; Hassiba El-Bouazzati; Gérard Vergoten; Bruno Quesnel; Christian Bailly
Journal:  Cancers (Basel)       Date:  2022-07-11       Impact factor: 6.575

7.  Distribution of subpopulations of dendritic cells in peripheral blood of patients treated with exogenous thyrotropin.

Authors:  Mariusz Stasiołek; Zbigniew Adamczewski; Bartosz Puła; Kinga Krawczyk-Rusiecka; Arkadiusz Zygmunt; Magdalena Borowiecka; Piotr Dzięgiel; Andrzej Lewiński
Journal:  Thyroid Res       Date:  2012-11-30
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.